Bevacizumab 10mg/kg - 14 days. NCCP National SACT Regimen. HSE.
Regulatory approval published by the Health Service Executive.
Citation
Bevacizumab 10mg/kg - 14 days, 2021, version number 6, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/212.pdfRegulatory approvals
Approved indications from this document for cancer drugs containing at least one biomarker.
| Indication | Statements |
|---|---|
| In combination with paclitaxel is indicated for first-line treatment of adult patients with HER2-negative metastatic breast cancer. | 1 |
Therapeutic response
Precision oncology relationships for therapeutic response derived from this document.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | HER2-negative | Invasive Breast Carcinoma | Bevacizumab, Paclitaxel |